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Introduction
Protein S (PS) is a vitamin K-dependent glycoprotein mainly synthesized in the liver and present in plasma, platelets and endothelial cells. 1 Plasma PS (350 nM) is distributed between two pools: approximately 40% circulates free, while about 60% is bound to the complement regulatory factor C4b-binding protein (C4BP). 2 Only C4BP molecules with a b-chain (C4BP-b + ) bind PS and, given the high affinity of this interaction (Kd = 0.1 nM), 2 all C4BP-b + present in plasma (~200 nM) is complexed with PS. 3 PS is a potent anticoagulant protein that down-regulates thrombin formation via two mechanisms. 4 On the one hand it stimulates the proteolytic inactivation of coagulation factors (F) Va and VIIIa by activated protein C (APC), 5 and on the other hand it enhances the inhibition of FXa by tissue factor pathway inhibitor (TFPI). 6, 7 Although free PS is the most active form, recent reports indicate that the PS-C4BP complex also exhibits APC-and TFPI-cofactor activities. 6, 8 Hereditary PS deficiency is a rare coagulation disorder associated with an increased risk of venous thrombosis. 9, 10 It usually occurs as a partial (heterozygous) deficiency and segregates as an autosomal dominant trait. Presently, more than 200 mutations impairing PS synthesis and/or function have been described in the PS gene (PROS1), and large deletions/duplications within the PROS1 locus have been identified as a relatively common cause of PS deficiency. 11, 12 Based on PS antigen and (APC-cofactor) activity levels, PS deficiency is classified as type I (low total and free antigen, reduced activity), type II (normal total and free antigen, reduced activity) and type III (normal total antigen, reduced free antigen and activity). However, since PS levels are strongly influenced by age, sex and hormonal status, 13 as well as by several acquired conditions, the diagnosis of PS deficiency states based on PS levels is far from straightforward in practice.
Type I and type III deficiencies account for 95% of cases of PS-deficiency and often occur together in the same family as phenotypic variants of the same genetic defect (mixed type I/III deficiency). 14 The reasons for the different phenotypic expression are poorly understood, but the agedependent increase in total PS is thought to play a role, as type III PS-deficient family members tend to be older than their type I-deficient relatives. 15 Differently, other families with PS deficiency only express the type III phenotype (pure type III deficiency). This type of PS deficiency is often, but not always, 16 associated with the PROS1 Ser 460 →Pro (Heerlen) mutation. 17 Although PS deficiency and, particularly, low levels of free PS 18, 19 are an established risk factor for venous thrombosis, risk estimates differ widely among studies, possibly reflecting the different severity of the underlying molecular defects. 20 Moreover, the few epidemiological studies that distinguish between type I and type III deficiencies are rather contradictory with respect to the risk of thrombosis associated with type III deficiency, which was found to be none, 21 the same as in type I deficiency 22 or intermediate. 23 To clarify this issue, we re-evaluated the risk of thrombosis associated with type I and type III PS deficiencies by Kaplan-Meier analysis of a large cohort of PS-deficient families. In support of our findings, we present a detailed characterization of type I and type III PS-deficient plasma based on the measurement of coagulation factor levels and ad hoc thrombin generation assays.
Design and Methods

Study population
Thirty families with type I and/or type III PS deficiency (242 individuals), identified at Padua University Hospital (Italy) between 1996 and 2002, were included in the Kaplan-Meier analysis. Families were ascertained via a proband who underwent thrombophilia screening after a first episode of venous (n=27) or arterial (n=3) thrombosis. Family members of each proband were invited to participate, and information on thrombosis history and age at onset of the first thrombotic event was recorded for each participant. Criteria for diagnosing venous thromboembolism have been previously reported. 24 PS deficiency was defined on the basis of free PS levels, 25, 26 applying a cutoff of 65%. The type of deficiency was assigned according to total PS levels, using a cut-off of 70%. These cut-offs were based on the variation of total and free PS levels in a population of 140 healthy individuals, irrespective of age and sex. Application of sex-specific cut-offs for total and free PS levels hardly affected the classification of the subjects.
Plasma samples for functional studies and blood cells for DNA extraction could be obtained for 23 of the 30 families. Blood samples were collected from probands and consenting family members for a total of 151 subjects. Patients on oral anticoagulant therapy (n=13) and women taking oral contraceptives (n=3) or hormone replacement therapy (n=3) at the time of blood collection were subsequently excluded, leaving 132 individuals available for study (Table 1 ). All participants provided informed consent to the study, which was carried out in accordance with the Helsinki protocol.
Blood collection and plasma preparation
Venous blood was drawn into 0.129 M sodium citrate (1:9 vol/vol) and platelet-poor plasma was prepared by centrifugation at 2000×g for 10 min. Plasma was aliquoted, snap-frozen and stored at -80 °C until use. Buffy coats were stored at -20 °C for later DNA isolation.
Measurement of plasma factor levels
In-house enzyme-linked immunosorbent assays were used to measure the plasma antigen levels of total, 27 free 28 and C4BP-bound PS, 8 as well as full-length TFPI. 29 Prothrombin levels were determined with a chromogenic assay, as previously described. 30 Antithrombin activity levels were determined using the Coamatic ® Antithrombin kit (Chromogenix, Mölndal, Sweden). The levels of all factors were expressed as percentages of the levels in normal pooled plasma.
Thrombin generation measurements
Thrombin generation was measured with the Calibrated Automated Thrombogram (CAT) method. 31 Coagulation was initiated with tissue factor (Innovin®, DADE-Behring, Marburg,
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haematologica | 2010; 95(9) To probe the activity of the APC/PS system, thrombin generation was initiated with 6.8 pM tissue factor and 30 mM phospholipids in the absence and presence of 5 nM human APC (Kordia Life Sciences, Leiden, The Netherlands), as described elsewhere. 30 The outcome of the assay was expressed as the ratio of the endogenous thrombin potentials (ETP) obtained in the presence and absence of APC, and normalized against the ETP ratio of normal pooled plasma measured in parallel (normalized APC-sensitivity ratio, nAPCsr). Since PS is a major determinant of this assay, 32 the nAPCsr is an indirect measure of the APC-dependent activity of PS. The nAPCsr varies between 0 and 10 and increases as the plasma level of PS (and hence its APC-cofactor activity) decreases.
To quantify the activity of the TFPI/PS system, thrombin generation was initiated with 1.36 pM tissue factor and 30 mM phospholipids in the absence and presence of neutralizing antibodies against PS (270 mg/mL polyclonal IgG; DAKO, Glostrup, Denmark) or TFPI (64 mg/mL monoclonal IgG1; Sanquin, Amsterdam, The Netherlands), essentially as described previously. 29 To exclude any contribution of the APC-dependent activity of PS, these measurements were conducted in the presence of 100 mg/mL anti-protein C polyclonal antibodies (DAKO). Moreover, corn trypsin inhibitor (Hematologic Technologies, Essex Junction VT, USA) was added to a final concentration of 30 mg/mL to prevent contact activation. The ratio of the thrombin generation peaks obtained in the absence and presence of anti-PS antibody (PS-ratio) is a measure of the TFPI-cofactor activity of PS, while the ratio of the thrombin generation peaks obtained in the absence and presence of anti-TFPI antibody (TFPI-ratio) is a measure of the activity of the TFPI/PS system as a whole. 29 Both ratios vary between 0 and 1 and increase as the TFPI-cofactor activity of PS decreases.
Genetic analysis
Buffy coats were available for 110 of the 132 eligible participants. Genomic DNA was extracted using the Wizard ® Genomic DNA Purification kit (Promega, Madison WI, USA). PROS1 mutation screening was performed by polymerase chain reaction-mediated amplification of each exon (including splicing junctions) and of the proximal promoter followed by direct sequencing. Primers and conditions (available on request) were chosen such as to avoid co-amplification of the highly homologous PS pseudogene. Whenever a PROS1 mutation was identified, all family members were tested for carriership of that mutation by high-resolution agarose gel electrophoresis, restriction analysis or direct sequencing, as detailed in Table 2 .
In families without apparent mutation, the possibility of a large deletion was verified by multiplex ligation-dependent probe amplification (MLPA) analysis using the SALSA MLPA P112 PROS1 kit (MRC-Holland, Leiden, The Netherlands). MLPA reactions were carried out according to the manufacturer's instructions. After the addition of GeneScan TM 600 LIZ ® Size Standard and HiDi TM formamide (Applied Biosystems, Foster City CA, USA), MLPA products were denatured at 80 °C for 2 min and separated by capillary electrophoresis on an ABI 3730 DNA analyzer (Applied Biosystems).
Carriership of the FV Leiden and prothrombin G20210A mutations was determined as previously described.
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Statistics
Kaplan-Meier analysis
Thrombosis-free survival was analyzed with the Kaplan-Meier method. The age at onset of the first thrombotic event for symptomatic individuals and the age at the time of inclusion in the study for asymptomatic subjects were used to evaluate the thrombosis-free survival time. Differences between the curves were assessed with the log-rank test.
General statistics
Data are reported as mean ± standard deviation (SD), unless otherwise indicated. Plasma factor levels were compared between groups with Student's t-test. Thrombin generation parameters were compared with the non-parametric Mann-WhitneyWilcoxon U test due to their non-normal distribution in some population subgroups. Correlations were expressed as Pearson coefficients (r). The determinants of thrombin generation parameters were identified by multiple regression analysis and their effects were expressed as unstandardized regression coefficients (B). Statistical analyses were performed with SPSS 14.0 for Windows (SPSS, Chicago IL, USA).
Results
Clinical evaluation
Two hundred and forty-two individuals belonging to 30 families with PS deficiency (28 with pure type I deficiency or mixed type I/III deficiency and two with pure type III deficiency) were investigated. Of the 30 probands, 18 presented with type I deficiency and 12 with type III deficiency. Out of 212 family members, 112 had normal PS levels and 100 were PS-deficient (55 type I and 45 type III). Detailed demographic and clinical characteristics of the study population are reported in the Online Supplementary Appendix.
The risk of thrombosis associated with PS deficiency was evaluated by Kaplan-Meier analysis. As expected, the cumulative proportion of thrombosis-free individuals was higher (P<0.001) in the normal group than in the PS-deficient group ( Figure 1A,B) . However, no significant difference in thrombosis-free survival was observed between type I and type III PS-deficient individuals in the whole cohort (probands and family members, Figure 1A ), nor after exclusion of probands ( Figure 1B ) or in probands only ( Figure 1C ). Results did not change when survival analysis was restricted to patients whose first thrombotic event had been deep-vein thrombosis and/or pulmonary embolism or when males and females were analyzed separately (data not shown).
Laboratory evaluation: characteristics of the study population
Plasma factor levels and thrombin generation were measured in a random subset of the population used for KaplanMeier analysis (23 families). After excluding patients taking oral anticoagulants and women on hormonal therapy, 132 individuals (53 normal, 59 type I deficient and 20 type III deficient) were available for plasma phenotyping (Table 1) . Of the 20 type III PS-deficient individuals, 18 were from families with mixed type I/III deficiency and only two from families with pure type III deficiency. However, two of the type III deficient individuals from a mixed type I/III family turned out to carry the PS Heerlen mutation (see below).
Females were over-represented among PS-deficient sub- Genotyping for the FV Leiden mutation identified eight heterozygous carriers in three different families. Twelve individuals belonging to five different families were heterozygous for the prothrombin G20210A mutation.
Plasma factor levels
Plasma levels of PS (total, free and C4BP-bound), prothrombin, antithrombin and full-length TFPI were measured in all subjects and compared between groups (Figure 2 ). Total PS levels ( Figure 2A) Figure 2D ) did not differ between normal (92.5±18.7%) and type I deficient individuals (88.8±12.0%), but they were significantly elevated in type III deficient individuals (104.1±16.0%, P=0.011 and P=0.001 versus normal and type I deficient individuals, respectively). This difference persisted after exclusion of carriers of the prothrombin G20210A mutation. Antithrombin levels ( Figure 2E ) were similar in all three groups. Finally, fulllength TFPI levels ( Figure 2F) were not different between normal (122.9±47.7%) and type III deficient individuals (121.3±31.4%), but were significantly reduced in type I deficient individuals (76.9±32.5%, P<0.001), as observed elsewhere. 33 All inter-group differences in plasma factor levels persisted after correction for age and sex.
Plasma levels of coagulation factors and inhibitors were correlated in the study population. The strongest correlations were observed between total, free and bound PS (total/free: r=0.885; total/bound: r=0.413; free/bound: r=0.434; P<0.001 for all three correlations), total PS and fulllength TFPI (r=0.607, P<0.001), and total PS and prothrombin (r=0.371, P<0.001). These correlations remained significant when normal and PS-deficient individuals were analyzed separately.
Activated protein C-cofactor activity of protein S
To quantify the activity of the APC/PS system, thrombin generation was measured at 6.8 pM tissue factor in the absence and presence of APC, and the nAPCsr was calculated. Since FV Leiden strongly influences this assay, FV Leiden carriers were excluded from the analysis.
Despite a large inter-individual variability, thrombin generation started earlier (shorter lag time) and was higher in PS-deficient plasma than in normal plasma, both in the absence and presence of APC (Online Supplementary Table  S1 ). In the absence of APC ( Figure 3A) , there was no difference between the ETP of normal and type I deficient individuals, but type III deficient individuals had significantly higher ETP values (P≤0.001). In the presence of APC ( Figure  3B ), the ETP of type I and type III deficient individuals were similar and approximately 3.5-fold higher than those of normal individuals (P<0.001). As a consequence, the nAPCsr ( Figure 3C ), was highest in type I deficient plasma, slightly lower in type III deficient plasma (P=0.057) and much lower in normal plasma (P<0.001). Thrombotic haematologica | 2010; 95(9) 
Tissue factor pathway inhibitor-cofactor activity of protein S
The activity of the TFPI/PS system was quantified by measuring thrombin generation at 1.36 pM tissue factor in the absence and presence of neutralizing antibodies against PS (αPS) or TFPI (αTFPI) and by calculating the PS-and TFPI-ratios. FV Leiden carriers were excluded.
Thrombin generation in the absence of antibodies was faster and higher in PS-deficient plasma than in normal plasma. However, this difference largely disappeared in the presence of antibodies, with only the lag time remaining slightly but significantly shorter in PS-deficient plasma (Online Supplementary Table S2 ). Also in this test, a large inter-individual variability was observed. In the absence of antibodies ( Figure 4A ), the peak height was virtually identical in type I and type III deficient individuals, and higher than in normal individuals (P≤0.011). Addition of αPS, and even more so addition of αTFPI, caused an increase in thrombin generation, due to the partial (αPS) or complete (αTFPI) inhibition of the TFPI/PS system. In the presence of αPS (Figure 4B ), the peak height was similar between normal and type III deficient individuals, while type I deficient individuals had slightly higher thrombin peaks, possibly due to their lower TFPI levels. In the presence of the αTFPI antibody ( Figure 4C ), normal and type I deficient plasmas yielded similar peak heights, which were lower than in type III deficient plasma (P=0.022 and P=0.010, respectively). The PS-ratio ( Figure 4D ) and TFPI-ratio ( Figure 4E ) increased progressively from normal to type III and type I deficient plasma. However, the difference between type I and III deficient individuals was only significant for the TFPI-ratio (P=0.034).
The determinants of the peak height of thrombin generation measured in the absence and presence of αPS or αTFPI antibodies, as determined by multiple regression analysis, are reported in the Online Supplementary Appendix.
Relationship between the normalized activated protein sensitivity ratio and the tissue factor pathway inhibitor ratio
Multiple regression analysis showed that free PS and fulllength TFPI levels were major determinants of both the nAPCsr (B=-0.37/10% PS, P<0.024; B=-0.10/10% TFPI, P=0.007) and the TFPI-ratio (B=-0.06/10% PS, P=0.011; B=-0.02/10% TFPI, P<0.001). Accordingly, the nAPCsr and the TFPI-ratio were strongly correlated in the population (r=0.629, P<0.001).
PROS1 mutation screening
Due to the availability of genomic DNA from at least one PS-deficient family member, PROS1 mutation screening was possible in 20 of the 23 families. By sequencing the Type I and type III protein S deficiency haematologica | 2010; 95 (9) 1567 coding region (including splicing junctions) and the proximal promoter, a PROS1 mutation was identified in 14 families (Table 2 ). In the six families in which no mutation was detected, MLPA analysis was performed to check for the presence of major rearrangements of the PROS1 gene. Two large deletions, spanning exons 2-15 and exons 9-11 were identified in two different families ( Figure 5 ). When genetic screening was extended to family members, the respective mutation or deletion was identified in 56/58 (96.5%) individuals classified as PS-deficient on the basis of PS levels and in 2/30 (6.7%) individuals classified as normal. The PROS1 Heerlen mutation was present in three related individuals, two with type III deficiency and one with PS levels within the normal range. All mutations were in the heterozygous state. In all families with mixed type I/III deficiency (except in the family with the Heerlen mutation), the same mutation accounted for type I as well as type III deficient members.
Interestingly, PS-deficient individuals from families with a PROS1 mutation or deletion had lower PS levels and higher nAPCsr, PS-ratio and TFPI-ratio than PS-deficient individuals from families without an identifiable genetic defect (data not shown). Thrombosis-free survival was not different between PS-deficient individuals with and without an identifiable PROS1 defect, but it was significantly reduced in carriers of a PROS1 mutation or deletion as compared to non-carriers (log-rank, P=0.039).
Discussion
Although the thrombotic predisposition associated with PS deficiency was recognized as early as 1984, 9,10 accurate risk estimates have been hindered by the difficulty of correctly diagnosing PS deficiency. Currently, type I PS deficiency is generally considered a risk factor for venous thrombosis, while conflicting results have been reported for type III deficiency. [21] [22] [23] In the present study we re-evaluated the thrombosis risk associated with type I and type III PS deficiencies by Kaplan-Meier analysis of a large cohort of PS-deficient families. Our data indicate that hereditary type III PS deficiency is a risk factor for venous thrombosis and that it confers a similar risk as type I PS deficiency (Figure 1) . Although type III deficient individuals were older than type I deficient individuals and advancing age is also a risk factor for thrombosis, the age at onset of thrombosis was not different between the two groups.
To account for this finding, genetic and functional studies were performed in 23 families with type I and/or type III PS deficiency (Table 1) . Genetic screening was possible in 20 families and yielded 12 PROS1 mutations (3 novel) in 14 families (Table 2) . Moreover, large PROS1 deletions were present in two families ( Figure 5 ). When family members were tested for carriership of the genetic defect found in the respective proband, an excellent co-segregation between PROS1 genotype and PS levels was observed. This not only confirms the causal role of the identified mutations, but also indicates that the free PS level cut-off used to define PS deficiency is appropriate and reliable. 26 For functional studies, the population was divided into three groups (normal, type I deficient and type III deficient) based on the levels of total and free PS. In line with other reports, 15, 16 type III PS-deficient individuals were older than their normal and type I deficient relatives. Moreover, they had higher PS (total, free and bound), prothrombin and TFPI levels than type I deficient individuals (Figure 2) . Interestingly, a recent study found that type III deficient individuals have elevated protein C levels as well. 16 Since the levels of all these factors increase with age, 32 our data support the hypothesis that type III deficient individuals from mixed type I/III families start out as type I deficient, but become type III deficient later in life because of the agerelated increase in total PS levels. 15 If this is the case, not only PS, protein C and prothrombin, but also other agedependent coagulation factors might be increased in type III deficient plasma. Differently, type I (but not type III) deficient individuals had markedly reduced TFPI levels, in line with the notion that the levels of PS and TFPI in plasma are strongly correlated. 33, 34 These additional abnormalities in plasma factor levels may synergize with the low PS levels to aggravate the hypercoagulable state associated with type I and type III PS deficiencies and underscore the importance of global phenotyping tests to evaluate the associated thrombosis risk.
Despite the expectation (based on PS and TFPI levels) that type I deficient plasma would be more procoagulant than type III deficient plasma, thrombin generation assays sensitive to the APC-and TFPI-cofactor activities of PS detected only a minor difference between type I and type III deficient plasmas ( Figures 3C and 4D,E) . Remarkably, the slightly lower nAPCsr of type III deficient individuals as compared to type I deficient individuals was not due to a lower ETP+APC, but to a higher ETP-APC (Figure 3) . Similarly, their lower TFPI-ratio was not due to a lower peak-Ab, but to a higher peak+αTFPI (Figure 4) . Multiple regression analysis pointed to age and prothrombin, in addition to free PS, as being the major determinants of elevated thrombin generation in type III deficient plasma. While high prothrombin levels are known to cause APC-resistance, 30 and to interfere with plasma assays that probe the APC-independent (TFPIdependent) anticoagulant activity of PS, 35 age might act by elevating the levels of several coagulation factors. 32 As the nAPCsr is a marker of the risk of venous thrombosis, 36 the data presented in Figure 3C support the outcome of the Kaplan-Meier analysis and confirm that type I and type III PS deficiencies confer similar risks of thrombosis. This finding is in line with that from a previous study, 22 but contrasts with data from other studies in which the risk of thrombosis associated with type III PS deficiency was found to be half that associated with type I deficiency 23 or not elevated at all. 21 A possible explanation for these discrepancies may be the population selection criteria, as it has been reported that type III deficient individuals from families with pure type III deficiency are not at risk of thrombosis, while those from mixed type I/type III deficient families are. 23 Also, no risk is generally attributed to the PROS1 Heerlen mutation. 17 In this respect, it is important to point out that in our study type III deficiency was defined solely on the basis of PS levels, irrespective of mutational status. Due to the small sample size, no distinction was made between type III deficient individuals originating from families with pure type III deficiency and mixed type I/III deficiency, although most belonged to mixed type I/III deficient families, and only two carried PROS1 Heerlen. Since type III PS deficiency is a heterogeneous category, a difference in thrombosis risk between type III deficient individuals from families with pure type III deficiency and those with mixed type I/III deficiency cannot be excluded and should be verified in a larger cohort of type III deficient individuals. In fact, the nAPCsr and PS-ratio of the two carriers of the Heerlen mutation in this study were lower than those of the 16 type III PS-deficient individuals belonging to families with mixed type I/III deficiency (nAPCsr 3.65 and 4.42 versus 5.29±1.93; PS-ratio 0.39 and 0.49 versus 0.69±0.13), underscoring the importance of family studies to distinguish pure type III from mixed type I/III PS deficiency.
In summary, we have shown that type III PS-deficient individuals from families with mixed type I/III deficiency have a similar risk of venous thrombosis as type I deficient individuals. This conclusion is based not only on KaplanMeier analysis, but also on a detailed characterization of the hypercoagulable states associated with type I and type III deficiencies, including the levels of several plasma factors, the APC-cofactor activity of PS and, for the first time, the TFPI-cofactor activity of PS. Although type I deficient individuals had lower PS and TFPI levels than type III deficient individuals, the latter had higher levels of prothrombin and possibly other age-dependent coagulation factors, resulting in an almost equivalent impairment of both anticoagulant functions of PS. These findings may have implications for the counseling and management of patients with type III PS deficiency.
